AIM ImmunoTech Inc. Common Stock (AIM)

AIM stock results show that AIM ImmunoTech missed analyst estimates for earnings per share the first quarter of 2024.

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

AIM stock results show that AIM ImmunoTech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

AIM stock results show that AIM ImmunoTech missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Companies Reporting Before The Bell • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter.

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.

The Dow Jones index closed lower by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Pre-market stock movers are worth checking out on Tuesday to catch up on all of the hottest stock market news for this morning!

The Dow Jones closed lower by over 50 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

The Dow Jones closed lower by more than 150 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

AIM ImmunoTech Inc (NYSE: AIM) announced that Roswell Park Comprehensive Cancer Center has reported the complete topline data from its Phase 1 study evaluating Ampligen (rintatolimod) as a component of a Chemokine-Modulating (CKM) regimen for the treatment of early-stage triple-